Back to discover
Disease

Nephritis

Late-stage therapeutic developmentEmerging research
MeSHNephritis
2
Publications
20
Clinical trials
12
Associated genes
3
Related proteins
2024
Latest publication
Current focus
C-reactive biologyPro-neuropeptide y biologyTherapeutic development
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2027.
  • 11 industry developments reported.
Upcoming Milestones
Clinical Milestones7View
Results posted 1
Results expected 4
Recently completed 1
Other updates 1
Industry & Market11View all 11
+6 more in the activity timeline below
Activity timeline18

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Voclosporinapproved

Original application approval — Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adul… (2022)

Obinutuzumabapproved

Original application approval — Chronic lymphocytic leukaemia (CLL) Gazyvaro in combination with chlorambucil is ind… (2014)

Belimumabapproved

Original application approval — Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, a… (2011)

Clinical trials

15 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

Phase 3 · Recruiting · Novartis Pharmaceuticals

A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)

Phase 3 · Recruiting · Alexion Pharmaceuticals, Inc.

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

Phase 3 · Active, not recruiting · Hoffmann-La Roche

The Randomized Controlled Trial of Finerenone Therapy for Pediatric Hennoch Scholein Nephritis With Mild Proteinuria

Phase 4 · Recruiting · Capital Institute of Pediatrics, China

Prednisolon Behandling Ved Akut Interstitiel Nefritis - et Randomiseret, Prospektivt Studie

Phase 4 · Recruiting · Region MidtJylland Denmark
Recruiting

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

Phase 3 · Recruiting · Novartis Pharmaceuticals

A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)

Phase 3 · Recruiting · Alexion Pharmaceuticals, Inc.

Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

The Randomized Controlled Trial of Finerenone Therapy for Pediatric Hennoch Scholein Nephritis With Mild Proteinuria

Phase 4 · Recruiting · Capital Institute of Pediatrics, China

Prednisolon Behandling Ved Akut Interstitiel Nefritis - et Randomiseret, Prospektivt Studie

Phase 4 · Recruiting · Region MidtJylland Denmark
Recently completed

A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis

Phase 3 · Completed · The University of Hong Kong

SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Diabetic and Non- Diabetic Lupus Nephritis Patients

Phase 4 · Completed · Mansoura University

Study of the Cardio Renal Effects of SGLT2 Inhibitors Among Diabetic and Non-diabetic Lupus Nephritis Patients

Phase 4 · Completed · Mansoura University

A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Voclosporin (23.7 mg Twice Daily) With Placebo in Subjects With Lupus Nephritis

Phase 3 · Completed · Aurinia Pharmaceuticals Inc.

Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety

Phase 4 · Completed · Shandong University

Weaning of Immunosuppression in Nephritis of Lupus

Phase 3 · Completed · Assistance Publique Hopitaux De Marseille

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2022emaOriginal application approval — Voclosporin· Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). source ↗
2014emaOriginal application approval — Obinutuzumab· Chronic lymphocytic leukaemia (CLL)&nbsp;Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.&nbsp;&nbsp;Follicular Lymphoma (FL)&nbsp;&nbsp;Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.&nbsp;&nbsp;&nbsp;Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.&nbsp;&nbsp;Lupus nephritis (LN)&nbsp;Gazyvaro in combination with mycophenolate mofetil (MMF) is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).&nbsp; source ↗
2011emaOriginal application approval — Belimumab· Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity&nbsp;(e.g., positive anti‑dsDNA and low complement)&nbsp;despite standard therapy. Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2012–2024
Major themes2
  • Hypertension, Renal1
  • Nephritis1
Leading journals2
  • Frontiers in immunology1
  • The American journal of pathology1
Leading researchers8
  • Coates PT1
  • Engel DR1
  • Gong Y1
  • Hailaiti D1
  • Hao XM1
  • Hickey MJ1
  • Holdsworth SR1
  • Kausman JY1
Affiliations (unnormalised)6
  • Beijing Jishuitan Hospital1
  • Centre for Inflammatory Diseases1
  • Dongzhimen Hospital1
  • School of Acupuncture-Moxibustion and Tuina1
  • School of Basic Medicine1
  • Sir Run Shaw Hospital1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CRP0.34MCTP20.33TAFA10.32NPY0.32DAPL10.31ZP40.31CCN30.31C5AR10.30GPM6A0.29KHDRBS30.29MTMR20.29MTUS20.29

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

C-reactive proteinvia CRP0.34Pro-neuropeptide Yvia NPY0.32C5a anaphylatoxin chemotactic receptor 1via C5AR10.30

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Inflammation of any part of the KIDNEY.

Identifiers
MeSHNephritis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.